2015
Personalised pharmacotherapy: an interim solution for antidepressant treatment?
Chekroud AM, Krystal JH. Personalised pharmacotherapy: an interim solution for antidepressant treatment? The BMJ 2015, 350: h2502. PMID: 25976040, DOI: 10.1136/bmj.h2502.Peer-Reviewed Original Research
2002
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms
Abi-Saab W, Seibyl JP, D'Souza C, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology 2002, 162: 55-62. PMID: 12107618, DOI: 10.1007/s00213-002-1057-7.Peer-Reviewed Original ResearchConceptsReceptor antagonismSchizophrenic patientsNeuroleptic-free schizophrenic patientsBrief Psychiatric Rating ScaleDouble-blind conditionsPsychiatric Rating ScaleTest dayRitanserin pretreatmentIntravenous infusionReceptor modulationAntipsychotic activityMale inpatientsReceptor stimulationPlasma prolactinCortisol levelsSchizoaffective disorderSchizophrenia symptomsPositive symptomsNegative symptomsRandomized orderPatientsRating ScaleBehavioral activationSymptomsRitanserin
1994
Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms
Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS. Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms. JAMA Psychiatry 1994, 51: 898-911. PMID: 7944878, DOI: 10.1001/archpsyc.1994.03950110058008.Peer-Reviewed Original ResearchConceptsVisual analog scaleAnalog scaleScale scoreVisual analog scale scoreYohimbine hydrochlorideAnalog scale scoreDouble-blind conditionsEffect of mCPPReceptor partial agonistEffects of ethanolNoradrenergic mechanismsIntravenous infusionPlasma levelsSerotonergic systemNoradrenergic systemPlaceboDiscriminative propertiesMale inpatientsYohimbinePlasma prolactinCortisol levelsPartial agonistSerotonergic contributionAlcohol dependenceDays of testing
1991
Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects
Seibyl J, Krystal J, Price L, Woods S, D'Amico C, Heninger G, Charney D. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Research 1991, 38: 227-236. PMID: 1754635, DOI: 10.1016/0165-1781(91)90013-f.Peer-Reviewed Original ResearchConceptsGrowth hormone responseEffects of ritanserinHealthy male subjectsHealthy human subjectsSelf-rated anxietyMCPP infusionAgonist mCPPCardiovascular effectsHT2 receptorCardiovascular responsesNeuroendocrine responsesRitanserinHormone responseMale subjectsCortisol elevationBehavioral responsesHuman subjectsMCPPSubjectsResponsePlaceboPremedicationChlorophenylpiperazineInfusionAntagonistMechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia
Deutch A, Moghaddam B, Innis R, Krystal J, Aghajanian G, Bunney B, Charney D. Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Research 1991, 4: 121-156. PMID: 1674882, DOI: 10.1016/0920-9964(91)90030-u.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsBrainHumansReceptors, DopamineReceptors, SerotoninSchizophreniaSchizophrenic PsychologyConceptsAtypical antipsychotic drugsAntipsychotic drugsDopamine D2 receptor antagonismD2 receptor antagonismAtypical profileNovel therapeutic strategiesDopamine D2 receptorsMechanism of actionAtypical agentsReceptor antagonismClinical dataD2 receptorsTherapeutic strategiesDrug profileDrugs implicationsMode of actionDrugsAntagonismClozapineRacloprideSerotoninSubtypesSchizophrenia
1990
Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine
Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine. JAMA Psychiatry 1990, 47: 577-585. PMID: 2112374, DOI: 10.1001/archpsyc.1990.01810180077011.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsObsessive-compulsive disorderReuptake inhibitorsComparison of fluvoxamineSerotonin receptor functionDouble-blind fashionGlobal response rateWeeks of treatmentBaseline depressive symptomsYale-Brown Obsessive Compulsive ScaleMechanism of actionObsessive Compulsive ScaleReuptake inhibitionDopaminergic functionPrincipal diagnosisDepressive symptomsResponse rateFluvoxamineDesipramineReceptor functionObsessive-compulsive symptomsDesipramine hydrochlorideCompulsive ScaleSymptomsFluvoxamine maleateClinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs.
Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. The Journal Of Clinical Psychiatry 1990, 51 Suppl: 44-50; discussion 51-2. PMID: 2182616.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsDepressive DisorderHumansProlactinReceptors, SerotoninSerotoninSerotonin AntagonistsTryptophanConceptsIntravenous L-tryptophanBrain serotonin functionAntidepressant drug actionRole of serotoninL-tryptophanThymoleptic drugsPlasma TrpView of evidencePRL responseNeuroendocrine effectsSerum prolactinSerotonin functionAntidepressant drugsClinical dataTherapeutic effectPreclinical studiesReceptor sensitivityClinical settingChallenge paradigmDrug actionRecent evidenceAntidepressantsProlactinDrugsDepressionSerotonin-Specific Drugs for Anxiety and Depressive Disorders
Charney DS, Krystal JH, Delgado PL, Heninger GR. Serotonin-Specific Drugs for Anxiety and Depressive Disorders. Annual Review Of Medicine 1990, 41: 437-446. PMID: 2139556, DOI: 10.1146/annurev.me.41.020190.002253.Peer-Reviewed Original ResearchMeSH KeywordsAnxiety DisordersDepressive DisorderHumansNeurotransmitter Uptake InhibitorsReceptors, SerotoninSerotoninSerotonin Antagonists
1989
Responses to i.v. L-tryptophan in MDMA users.
Price LH, Ricaurte GA, Krystal JH, Heninger GR. Responses to i.v. L-tryptophan in MDMA users. NIDA Research Monograph 1989, 95: 421-2. PMID: 2577044.Peer-Reviewed Original Research